PhD, BSc, CEO
Dr. Dayan Goodenowe is a PhD neuroscientist, biochemist, synthetic organic chemist, inventor, and clinical research expert. In 1999, he invented and patented a revolutionary ion cyclotron resonance mass spectrometry technology that made it possible to monitor human biochemistry comprehensively for the first time in history.
Using this advanced technology, Dr Goodenowe analyzed blood samples from tens of thousands of persons of all ages, of all races, and of multiple countries. The biochemistry of healthy persons was compared to persons suffering from disease. A diverse range of over 20 diseases, from autism to dementia and from colon cancer to heart disease, was studied. The biochemistry of young versus old and all-cause mortality was studied. This research led to his discovery that early mortality and each human disease has a biochemical prodrome.
These findings contributed to an extensive patent portfolio of diagnostic tests for the early detection and screening of diseases such as specific cancers (colon, pancreatic, ovarian, breast, lung, prostate, and many more), autism, multiple sclerosis, Parkinson’s, ALS, Alzheimer’s, dementia, bipolar disease, schizophrenia, unipolar depression, cardiovascular disease, and others. Dr Goodenowe created the ProdromeSCAN blood test, which measures all of the key prodrome biomarkers and offers advanced laboratory test interpretation training for health practitioners.
Websites:https://drgoodenowe.com/https://restorativehealth.drgoodenowe.com/https://prodrome.com/
